Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.

Authors:
Li DY; Liu X; Huang JY; Hang WL; Yu GR and 1 more

Journal:
Ther Adv Respir Dis

Publication Year: 2024

DOI:
10.1177/17534666241232561

PMCID:
PMC10901065

PMID:
38414439

View on PubMed View on PMC View Publisher

Journal Information

Journal Title: Ther Adv Respir Dis

Detailed journal information not available.

Publication Details

Subject Category: Respiratory System

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score

4/6

66.7% Transparent

Transparency Indicators

Click on green indicators to view evidence text

Core Indicators

Data Sharing

Code Sharing

COI Disclosure

Evidence found in paper:

"The authors declare that there is no conflict of interest."

Funding Disclosure

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: NATCM’s Project of High-level Construction of Key TCM Disciplines."

Protocol Registration

Evidence found in paper:

"Trial registration: This study protocol was registered with PROSPERO (registration number: CRD42023411272)."

Open Access

Paper is freely available to read

Additional Indicators

Replication

Novelty Statement

Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025